key: cord-0988527-5xs437td
authors: Li, Wenwei; Chen, Yaozong; Prévost, Jérémie; Ullah, Irfan; Lu, Maolin; Gong, Shang Yu; Tauzin, Alexandra; Gasser, Romain; Vézina, Dani; Anand, Sai Priya; Goyette, Guillaume; Chaterjee, Debashree; Ding, Shilei; Tolbert, William D.; Grunst, Michael W.; Bo, Yuxia; Zhang, Shijian; Richard, Jonathan; Zhou, Fei; Huang, Rick K.; Esser, Lothar; Zeher, Allison; Côté, Marceline; Kumar, Priti; Sodroski, Joseph; Xia, Di; Uchil, Pradeep D.; Pazgier, Marzena; Finzi, Andrés; Mothes, Walther
title: Structural Basis and Mode of Action for Two Broadly Neutralizing Antibodies Against SARS-CoV-2 Emerging Variants of Concern
date: 2021-08-03
journal: bioRxiv
DOI: 10.1101/2021.08.02.454546
sha: 635ccde6914ad1491ef870045ff262ab3f56cb7b
doc_id: 988527
cord_uid: 5xs437td

Emerging variants of concern for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can transmit more efficiently and partially evade protective immune responses, thus necessitating continued refinement of antibody therapies and immunogen design. Here we elucidate the structural basis and mode of action for two potent SARS-CoV-2 Spike (S) neutralizing monoclonal antibodies CV3–1 and CV3–25 that remained effective against emerging variants of concern in vitro and in vivo. CV3–1 bound to the (485-GFN-487) loop within the receptor-binding domain (RBD) in the “RBD-up” position and triggered potent shedding of the S1 subunit. In contrast, CV3–25 inhibited membrane fusion by binding to an epitope in the stem helix region of the S2 subunit that is highly conserved among β-coronaviruses. Thus, vaccine immunogen designs that incorporate the conserved regions in RBD and stem helix region are candidates to elicit pan-coronavirus protective immune responses.

Introduction 49

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the third coronavirus to 50 enter the human population since 2003 and is responsible for the coronavirus disease of 2019 51 pandemic (Dong et al., 2020; Zhu et al., 2020) . While over ~1 billion vaccines have 52 been administered as of today (Baden et al., 2020; Folegatti et al., 2020; Logunov et al., 2021; 53 Polack et al., 2020; Sadoff et al., 2021a; Sadoff et al., 2021b; Voysey et al., 2021) , the 54 pandemic remains uncontrolled in many countries and new variants, including the B.1.1.7 55 (SARS-CoV-2 α), B.1.351 (β), P.1 (γ), and B.1.617.2 (δ), are outcompeting previous variants 56 due to higher transmissibility and elevated immune evasion (Campbell et al., 2021; Hoffmann et 57 al., 2021; Planas et al., 2021a; Planas et al., 2021b; Prévost and Finzi, 2021; Volz et al., 2021) . 58

The spike protein (S) on the surface of the virus mediates entry into cells and is a prominent 59 target for the host immune response including neutralizing antibodies. Consequently, S is a 60 main immunogen for vaccine design. The Moderna, Pfizer-BioNTech, Johnson & Johnson and 61 single particle cryo electron microscopy (SP cryoEM) of a soluble trimer comprising most of the 68 ectodomain (Walls et al., 2020; Wrapp et al., 2020) , as well as by cryo-electron tomography 69 (cryoET) and SP cryoEM of native virus particles (Ke et al., 2020; Turoňová et al., 2020; Yao et 70 al., 2020) . These studies have revealed several distinct prefusion conformations wherein three 71 RBD adopt up or down orientations. Receptor ACE2 binds and stabilizes RBD in the up 72 conformation (Lan et al., 2020; Shang et al., 2020; Xiao et al., 2021; Xu et al., 2021) . Single 73 molecule fluorescence resonance energy transfer (smFRET) imaging of single spike molecules 74 on the surface of virus particles has provided real-time information for transitions between both 75 RBD-up and down conformations through one necessary intermediate (Lu et al., 2020) . 76

Antibodies isolated from convalescent patients, vaccinated individuals and previous work on the 77 related SARS-CoV-1 and MERS-CoV viruses can be classified by their specificity for three main 78 epitopes: the RBD, the N-terminal domain (NTD) and the S2 subunit (Barnes et al., 2020b; 79 Jennewein et al., 2021; Ju et al., 2020; Liu et al., 2020; Montefiori and Acharya, 2021; Ullah et 80 al., 2021) . For each class the conformational preferences for either RBD-up or RBD-down trimer 81 configurations have been described. Antibodies directed against the RBD are often attenuated 82 against emerging variants of concern due to escape mutations (Greaney et al., 2021a; Liu et al., 83 2021; Starr et al., 2021; Weisblum et al., 2020) . Although immune responses elicited by existing 84 vaccines do offer protection to varying degrees against all known variants of concern 85 (Skowronski et al., 2021; Tauzin et al., 2021) , a booster shot to ensure sufficient protection from 86 future emerging variants might be needed. Moreover, SARS-CoV-2 is the third β -coronavirus 87 after SARS-CoV-1 and MERS-CoV to be transferred to humans in the 21 st century and given 88 the large natural reservoir of similar viruses in species such as bats (Anthony et al.; Ge et al., 89 2013; Letko et al., 2020; Menachery et al., 2015; Menachery et al., 2016; Wang et al., 2018) , 90 another pandemic caused by a new coronavirus is likely to happen again. These coronaviruses 91 possess a conserved S2 domain, which raises the possibility of cross-reactive antibodies and 92 cross-reactive vaccines. SARS-CoV-2 S is approximately 75% homologous to SARS-CoV-1 and 93 35% to MERS S (Grifoni et al., 2020; Zhou et al., 2020) . Various cross-reactive antibodies have 94 been identified (Hoffmann et al., 2020; Jennewein et al., 2021; Ma et al., 2020; Ng et al., 2020; 95 Song et al., 2020; Tian et al., 2020; Wang et al., 2020; Wang et al., 2021) . Recently isolated 96 antibodies capable of cross-neutralizing human coronaviruses bind to the conserved stem helix 97 region on S2, reviving hopes for pan-coronavirus vaccines (Pinto et al., 2021; Sauer et al., 2021; 98 Zhou et al., 2021) . to assign a structure for the high-FRET state (~0.8), this is the first time that we can generate 190 dynamic and static data for S on virus particles produced in the same cell type and assess them 191 in parallel by smFRET and cryoET. Overall, there is qualitative agreement between cryoET and 192 smFRET about how CV3-1 and CV3-25 alter the conformational landscape of S. Above 193 mentioned caveats make quantitative comparisons currently impossible. smFRET may detect 194 more dynamic features while cryoET may emphasize static features as previously discussed for 195 the HIV-1 spike protein (Li et al., 2020) . 196 lower than 7 Å, but there was additional density for CV3-25 in the C-terminal stem region. 3D 261 classification of the Cryo-EM data barely improved the local density suggesting incomplete Fab 262 saturation for all available binding sites. Nevertheless, the data suggested that CV3-25 binds to 263 the lower stem of the soluble HexaPro S. 264

Given that soluble S trimers are truncated, lack the transmembrane region, and feature a T4 265 foldon, we reasoned that cryoET of native spike proteins embedded into virus particles could 266 provide more insight into CV3-25's epitope. We used cryoET followed by subtomogram 267 averaging of ~7000 prefusion spikes to examine CV3-25 binding to S B.1.1.7 . Subclassification 268 revealed that about half of S had two CV3-25 Fabs bound to the stem of S2, and the other half 269 had only one CV3-25 Fab bound ( Figure S5 ). We further aligned the subtomograms with a 270 mask for two CV3-25 Fabs to arrive at ~10 Å resolution map. This structure places the CV3-25 271 epitope within the connecting domain (CD) of the stem helix ( Figure 5A , B, F). Density for the 272 second Fab was weaker since ~half of spikes had only one CV3-25 Fab bound. 273

As discussed above, classification of the spike structures into 3-RBD-down, 1-, 2-or 3-RBD-up 274 revealed an overall shift towards activation for CV3-25 bound S ( Figure 2E To gain atomic insight, we screened S2 peptides for binding to CV3-25 with the goal of isolating 285 peptides suitable for X-ray crystallography. The first insight that CV3-25 binds a linear peptide 286 was gained from Western blotting following SDS-PAGE. CV3-25 was clearly able to bind to S2 287 as well as the S2-containing S precursor under fully denaturing conditions and independently of 288 N-linked glycans ( Figure S6A , B). We then tested a set of peptides (15-mer) spanning the entire 289 S2 subunit including the connecting domain and performed two rounds of ELISA to identify 290 peptides capable of binding CV3-25 ( Figure 5C -E). The identified peptides (#288 and #289) 291 were also tested in competition assays and the binding was quantified using SPR assays 292 (Figures S6C, D) . Peptide #289 was the most potent in all assays with a K D of 29 nM and 293 efficiently blocked CV3-25 neutralization ( Figure S6E , 6F). Peptides #288 and #289 mapped to 294 the S2 stem helix region ( Figure 5F ), consistent with the CV3-25 binding region indicated in the 295 cryoET averaged structure. 296 297

To obtain molecular insight into CV3-25 interaction with the S2 stem peptide, we determined the 299 co-crystal structure of CV3-25 Fab with a synthetic peptide spanning residues 1140-1165 300 (26mer) of SARS-CoV-2 spike. The structure was solved to 2.1 Å resolution and allowed us to 301 resolve 20 of the 26 residues in relation to the Fab paratope ( Figure 6 , Figure S7 , Table S2 ). 302

When bound to CV3-25 Fab, the peptide adopted a bent conformation with the N-terminal half 303 of the peptide (residues 1146-DSFKEELDKYFK-1157) forming an α -helix and the C-terminal 304 half a random coil (residues 1158-NHTSPDVD-1165) with a bend of ~95º between the two 305 ( Figure 6A ). This bent conformation fit well with the long complementary determining region 306 (CDR) H3 loop of the Fab (16 aa long) that is stabilized by extensive H-bonds, salt bridges and 307 intra-molecular π -π stacking between residues Y 1155 and H 1159 of the peptide ( Figure 6B -D and 308 Figure S7 ). A rare CDR H3 disulfide bond between residues C 99 and C 100D also stabilizes the 309 CDR H3 hairpin that tightly associates with the S2 peptide random coil. Interestingly, the S2 310 stem region recognized by CV3-25 is conserved among the B lineage of β -coronaviruses 311 ( Figure 6F ), with several key epitope residues also conserved among A, C, and D lineages. This 312 suggests that CV3-25 displays cross-reactivity with coronaviruses beyond the B-lineage. 313

Furthermore, although crystallographic analyses confirm residues 1149 to 1165 of the S2 stem 314 to interact with CV3-25 ( Figure 6D ), SPR analyses using S2 peptide truncations indicate that 315 CV3-25 may also interact with residues following D 1165 , the terminal S2 residue used in 316 crystallographic studies. These contacts could be mediated by the light chain of CV3-25 that is 317 positioned to accommodate the C-terminal extension of the peptide ( Figure 6A ). Of note, the S2 318 recognition site and angle of approach of CV3-25 differentiate it from B6, the only reported anti-319 MERS-CoV S2 NAb as well as CC40.8 and S2P6, the only two known human anti-SARS-CoV-2 320 S2 NAbs (PDBs not available) (Pinto et al., 2021; Sauer et al., 2021; Zhou et al., 2021) Here we describe the structures and mode of action of two potent anti-SARS-CoV-2 Spike 348 antibodies. Both antibodies remained effective against emerging variants of concern and 349 therefore were prime candidates to elucidate mode of action and identify epitopes with pan-350 coronavirus activity. CV3-1 stabilized the receptor-binding domain (RBD) in the "RBD-up" 351 conformation and triggered potent shedding of S1. The ability of CV3-1 to neutralize variants of 352 concern correlated with its ability to shed S1 and inactivate S. In contrast, CV3-25 bound to a 353 highly conserved epitope in the stem helix in the S2 subunit and inhibited membrane fusion. We 354 believe that both epitopes of these two antibodies are of interest for passive and active 355 immunization strategies against emerging variants. 356

The cryoET structure of CV3-1 to S suggested binding to the 485-GFN-487 loop of RBD, an 357 interpretation confirmed by mutagenesis. While mutations in these positions abrogate the 358 binding of CV3-1 to S, they are rarely observed among circulating strains, suggesting that they 359 are associated with a high fitness cost likely due to their importance in ACE2 interaction. 360

Interestingly, CV3-1 exhibited potent agonist features indicating that it hits an allosteric site that 361 is critical for the ability of ACE2 to induce conformational changes that lead to fusion. Consistent 362 with this observation, CV3-1 induced potent shedding and the straightening of spikes indicative 363 of allosteric signaling from the RBD all the way to the S2 stem region. This allosteric signaling 364 likely weakens the S1-S2 interface leading to the observed shedding of S1. While CV3-1 is 365 specific against SARS-CoV-2, it remained active against all tested variants of concern and 366 variants of interest and protected K18-hACE2 transgenic mice from lethal challenges using the 367 B.1.351 variant of concern. The potent agonist features within the ACE2 binding site may also 368 open an opportunity for small molecule inhibitors that prematurely activate S not unlike CD4 369 mimetics in the case of HIV-1 envelope (Laumaea et al., 2020) . 370

The structures of CV3-25 with a S peptide and intact S on the surface of virus particles revealed 371 that it binds to the S2 stem in a region conserved among β-coronaviruses. Unlike other recently 372 reported anti-S2 antibodies, CC40.8 and S2P6, which mainly recognize the stem helix and 373 barely interact with the hinge region (Pinto et al., 2021; Zhou et al., 2021) , CV3-25 also engages 374 the hinge peptide known to be responsible for the tilting of spikes with respect to the membrane 375 (Ke et al., 2020; Turoňová et al., 2020) . This added ability of CV3-25 likely offers an advantage 376 in capturing an easily accessible epitope in the hinge region and subsequently progressively 377 twisting the helix to establish contact with the α-helical region of the stem. The relative 378 conservation of this hinge is likely related to the observed allosteric communication from the 379 RBD all the way down to S2. The post-fusion conformation of S forms a six-helix bundle 380 structure when pulling two membranes together for fusion. This conformational change probably 381 involves unwinding of the stem helix and loop to helix transition for the loose loop at the lower 382 end. CV3-25 binding at both helix region and the random coil at the stem helix likely interrupts 383 this S2 refolding, thus inhibiting membrane fusion. 384

One of the most exciting aspects of CV3-25 is its linear peptide epitope, which offers easy 385 access to exploration of its potential as an immunogen. As the structure of the native S on the 386 surface of virus particles revealed, access of CV3-25 is hindered by the need for rotation of the 387 stem helix. However, such conformational readjustment is not needed for an immunogen. As 388 such, eliciting antibodies targeting this S2 stem epitope using peptide or scaffold-presented 389 peptide immunogens is predicted to be easier than when the entire spike trimer is the antigen. 390

The potential of the CV3-25 epitope described herein should be explored as a candidate 391 immunogen for vaccines that could be effective against all emerging variants and possibly 392 exhibit pan-coronavirus efficacy. Structural Biology 197, [191] [192] [193] [194] [195] [196] [197] [198] Hoffmann, M., Arora, P., Groß, R., Seidel, A., Hörnich, B. Zhou, P., Yuan, M., Song, G., Beutler, N., Shaabani, N., Huang, D., He, W.-t., Zhu, X., 718 Callaghan, S., Yong, P., et al. (2021) . A protective broadly cross-reactive human antibody 719 defines a conserved site of vulnerability on beta-coronavirus spikes. bioRxiv, 720 2021.2003.2030.437769. 721 Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R. (Popov and Bourenkov, 2003) 1048 Cytokine mRNA levels, Brain **** **** **** **** *** ** ** **** **** **** **** *** *** * ** Figure S1 

SARS-CoV-2 Spike peptide ELISA (enzyme-linked immunosorbent assay) The SARS-CoV-2

template was generated using the NTD (residues 12-305) from PDB entry 7LY31, the RBD 964 (residues 306-541) and S1-S2 core (residues 542-1139) from 6XKL, and the S2 stem helix 965 from 6XR8 with the "fit-in-map" function in chimeraX. 966 (G) A S2-stem-peptide based superimposition of the variable region from the CV3-25-peptide 967 crystal structure (yellow and blue) with the cryo-EM model mimics the one-Fab-bound state. The 968 discrete, feeble and nearly-isotropic density around the S2-helix indicates that there is a high 969 degree of local dynamic motion and a diverse collection of Fab-stem-peptide 970 conformations/orientations relative to the rigid S2 core that may transiently coexist. immobilized on a protein A chip either to 2500 or 7500 RU prior to peptide injection. The S2 996 peptides of different truncations or the equivalent scrambled peptides were injected at the 997 indicated concentrations. The peak response was taken to be the background corrected 998 response at the steady state where the binding reached equilibrium. The data shown is from 999 three independent experiments. 1000 (E) Pseudoviruses encoding for the luciferase reporter gene and bearing SARS-CoV-2 Spike 1001 D614G were used to infect 293T-hACE2 target cells. Pseudovirions were incubated with CV3-1002 25 mAb (10 µg/mL) in presence of increasing concentrations of S2 peptide #289, or peptide 1003 scramble as a control, for 1h at 37°C prior infection of 293T-hACE2 cells for 48h at 37°C. Error 1004 bars indicate means ± SEM. These results were obtained from at least 3 independent 1005experiments. Statistical significance was tested using (C) one-way ANOVA with a Holm-Sidak 1006 post-test or (E) an unpaired T test (**p < 0.01; ***p < 0.001; ****p < 0.0001; ns, non significant). σ . The N-terminal non-contact 1014 S2 residues D 1146 to K 1148 are omitted for clarity. The surface of CV3-25 Fab is represented with 1015 CDR H1, CDR H2, and CDR H3 colored in green, cyan and pink respectively. 1016 (C) V H and V L sequence alignments of affinity matured CV3-25 and its germline IGHV5-51 along 1017 with two other S2-binding Abs, CC40.8 (anti SARS-CoV-2) 6, 17 and B6 (anti MERS-CoV) 5 . CDR 1018 sequences are colored as indicated in Figure 6 . The buried surface residues (BSA > 0 Å) as 1019 calculated by PISA 15 are shaded in grey. Contact residues involved in salt-bridges or H-bonds to 1020 S2 peptide are marked above the sequence with (+) for the side chain and (-) for the main chain. 1021Somatically mutated residues as compared to the germline sequence are highlighted with blue 1022 boxes. The peptide binding paratope of CV3-25 is predominantly formed by CDRs of the heavy 1023 chain which contributes ~95% of the overall S2 buried surface area (BSA) from the Fab (BSA of 1024 637.6 Å 2 and 27.6 Å 2 for the heavy and light chain, respectively). The paratope-epitope interface 1025 is comprised mostly of hydrophilic interactions which includes an extensive network of charge 1026 complementarity ( Fig. 6B and C) 

The plasmids expressing the wildtype SARS-CoV-2 Spike was previously reported (Hoffmann et 1067 (Hoffmann et al., 2020 . The plasmid encoding for SARS-CoV-2 S RBD (residues 319-541) fused with a 1068 hexahistidine tag was previously described (Beaudoin-Bussières et al., 2020 defocus range was -2 to -6 µm and 9 frames were saved for each tilt angle. Detailed data 1120 acquisition parameters are summarized in Table S1 . 1121Frames were motion-corrected using Motioncorr2 (Zheng et al., 2017 )(Zheng et al.,2017 to their perpendicular positions to the viral surface were excluded. Subsequent processing was 1137 performed by using I3 (Winkler, 2007) with 2 x and 4 x binned tomograms. 1138All the density maps were segmented in the UCSF Chimera (Pettersen et al., 2004) , and 1139ChimeraX (Goddard et al., 2018; Pettersen et al., 2021) for experiments by using the primer sets recommended by Jackson Laboratory. 1150

For all in vivo experiments, the 6 to 8 weeks male and female mice were intranasally challenged 1152with 1 x 10 5 FFU in 25-30 µL volume under anesthesia (0.5 -5 % isoflurane delivered using 1153precision Dräger vaporizer with oxygen flow rate of 1 L/min). For Nab treatment using 1154prophylaxis regimen, mice were treated with 250 µg (12.5 mg/kg body weight) of indicated 1155antibodies ( 

The split nanoluc assay was used to measure antibody-mediated inhibition of virus-cell fusion 1196 (Yamamoto et al., 2019 Lu et al., 2020) . 

Lentiviruses carrying SARS-CoV-2 spikes were prepared similarly as previously described (Lu 1220 (Lu et al., 2020 . Two short peptides labeling tags (Q3: GQQQLG; A4: DSLDMLEM) were 1221introduced into designed positions in the S1 subunit on the plasmid encoding S B. value with a value below 3 considered acceptable. 1281

The purified non-tagged SARS-CoV-2 HexaPro spike (293F produced) 

Motion correction, CTF estimation, particle picking, curation and extraction, 2D classification, ab 1297initio model reconstruction, volume refinements and local resolution estimation were carried out 1298in cryoSPARC (Punjani et al., 2017; Rubinstein and Brubaker, 2015) . An initial SARS-CoV-2 1299 spike model (PDB: 6XKL (Hsieh et al., 2020) ) with single-RBD up was used as a modeling 1300template. The NTDs were initially modelled from PDB entry 7LY3(McCallum et al., 2021) . The 1301initial docking model for CV3-25 Fab was taken from the crystallography model in this study. 1302 Automated and manual model refinements were iteratively carried out in ccpEM (Burnley et al., 1303 2017), Phenix (real-space refinement) (Liebschner et al., 2019) and Coot(Emsley and Cowtan, 1304 2004) . Geometry validation and structure quality evaluation were performed by EM-Ringer 1305( Barad et al., 2015) and Molprobity (Chen et al., 2010) . Model-to-map fitting cross correlation 1306and figures generation were carried out in USCF Chimera, Chimera X (Goddard et al., 2018; 1307 Pettersen et al., 2004 Pettersen et al., 2021) and PyMOL (The PyMOL Molecular Graphics 1308System, Version 2.0 Schrödinger, LLC.). The complete cryoEM data processing workflow is 1309shown in Figure S2 and statistics of data collection, reconstruction and refinement is described 1310in Table S2 . 1311

CV3-25 Fab was prepared and purified as described (Ullah et al., 2021) . 10 mg/mL of CV3-25 1313 was mixed with synthetic S2 peptide spanning residues 1153-1163, 1153-1167 or 1140-1165 1314 (26mer) (MPD) as the cryoprotectant. X-ray diffraction data was collected at the SSRL beamline 9-2 and 1322was processed with HKL3000 (Minor et al., 2006) . The structure was solved by molecular 1323 replacement in Phenix(Liebschner et al., 2019) using a CV3-25 framework model generated by 1324SAbPred (Dunbar et al., 2016) . Iterative cycles of model building and refinement were done in 1325Coot (Emsley and Cowtan, 2004) and Phenix. Structural analysis and figure generation were 1326 performed in PyMOL and ChimeraXFab-peptide interface and buried surface area were 1327 determined in PISA(Krissinel and Henrick, 2007) . Data collection and refinement statistics are 1328shown in Table 1 . 1329

Using the standard calcium phosphate method, 10 were lysed with lysis buffer, as described above. Lysates were treated with PNGase F (NEB) 1410following the manufacturer's instructions or mock treated as a control. The lysates were then 1411Western blotted with the CV3-25 antibody, as described above. 1412

Data were analyzed and plotted using GraphPad Prism software (La Jolla, CA, USA